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ABSTRACT 
To improve both safety and stability of the vaccines used in the field to vaccinate foxes against 
rabies by the oral route, a recombinant vaccinia virus, expressing the glycoprotein of rabies virus 
(VVTGgRAB) has been developed. VVTGgRAB innocuity was verified in target species and in 
domestic animals as well as in numerous wild animal species that could compete with the red fox 
in consuming vaccine baits in Europe. 
Oral immunization of foxes, by distributing VVTGgRAB vaccine-baits, was undertaken in the whole 
of the infected area of Belgium (10 000 km2). Five campaigns of fox vaccination covering the whole 
infected area were carried out from the autumn of 1989 until 1991. Each time, 150 000 
vaccine-baits were dispersed by air at a mean density of 15 per km2. 
These campaigns induced a drastic decrease in the incidence of rabies and the elimination of the 
disease from 80% of the initial infected area. Regarding the geographical evolution of rabies in 
Belgium and in adjacent regions in neighbouring countries, new spatial strategies for bait dispersal 
were planned for 1992, 1993 and 1994 : successive restricted campaigns were carried out along 
political borders only. These campaigns induced a new decrease of incidence; no rabid foxes could 
be detected in 1993 in spite of an improved epidemiological surveillance. In 1994, rabies was 
confirmed again in 13 foxes collected in a region situated close to the French border. 
These cases demonstrate the persistence of a focus of rabies on the border and justify further 
restricted campaigns of vaccination. 
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The main vector of the current epidemic of sylvatic rabies in Europe is the red fox. Here, the term 
vector means the animals most susceptible to rabies in a region at a given time, solely 
responsible for maintaining the infection. All other species are victims, even if they are able to 
transmit rabies. Consequently their destruction or immunization have no effect on the disease 
cycle. Whereas rabies among domestic animals can be controlled by appropriate prophylactic 
measures, it poses a bigger problem in wildlife, and until 1960 the only possible available means 
was considered to be the reduction of vector populations. 
As in most other European countries, control measures by reducing the fox population were only 
temporarily effective and did not stop the spread of the disease. For this reason, other methods 
such as oral immunization of foxes against rabies needed to be assessed. The principle of this 
control method consists of the immunization of a fraction of the fox population sufficient to 
reduce the efficacy of rabies transmission, thus disrupting the viral infection chain (Anderson et 
al., 1981). Research focussed on oral vaccination, the only procedure appropriate for the 
immunization of wild foxes in the field (distribution of vaccine baits). There have been numerous 
experiments in which procedures varied according to the type of vaccine and the type of bait 
used as vaccine vehicle. The method of vaccinating wild animals against rabies was developed 
first in the USA (Baer, 1975), then in Europe (Steck et al., 1982), and used for the first time in the 
field in October 1978 in Switzerland. Since 1978, several European countries have conducted at 
different times, large scale field trials of oral vaccination of foxes using the SAD, standard or B 19 
modified (Schneider and Cox, 1983), attenuated strain of rabies virus. The promising results 
obtained with these vaccination campaigns attest to the feasibility and efficacy of the method. 
However, the use of attenuated rabies virus still remains controversial as far as innocuity and 
stability are concerned, since these virus strains retain pathogenicity for some non target species 
(Artois et al., 1992; Bingham et al., 1992) and are heat-sensitive. Moreover attenuated strains of 
rabies virus may still be pathogenic for man; therefore humans exposed to those strains must be 
treated using standard procedures. Therefore, recent work has focused on technical adjustments, 
particularly the type of vaccine. In order to improve both the safety and the stability of the 
vaccine used, a recombinant vaccinia virus which expresses the immunizing glycoprotein of 
rabies virus has been developed and extensively tested in the laboratory as well as in the field. 
This vaccine is currently being used on a large-scale in France, the Grand Duchy of Luxemburg 
and Belgium. Field trials are also in progress in the USA for oral vaccination of raccoons. 
Development of a vaccinia-rabies vector vaccine 
The glycoprotein of rabies virus is the sole viral protein present on the external surface of the viral 
membrane. It is the only viral antigen capable of eliciting the production of rabies virus-
neutralizing antibodies and has been shown to be capable of conferring immunity to rabies. Thus, 
the rabies virus glycoprotein is an ideal candidate for the construction of a subunit marked 
vaccine. 
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The rabies virus glycoprotein gene (ERA strain) has been inserted into the thymidine-kinase (TK) 
gene of vaccinia virus (Copenhagen strain) (VV), generating a selectable TK-virus (Kieny et al., 
1984; Wiktor et al., 1984) known as VVTGgRAB, which is safer than the parental strain (Buller et al., 
1985). VVTGgRAB has been tested for efficacy and safety in the main target species in Western 
Europe (Blancou et al., 1986) and North America: fox, raccoon and striped skunk. The duration of 
protection conferred by VVTGgRAB (a minimum of 18 months in adult foxes) corresponds to the 
length required for fox vaccination in the field due to the high turnover of the fox population. 
The preclusion of epizootiological risks, such as the emergence of asymptomatic carriers of wild 
rabies virus, is also of major importance. 
This situation could occur in the field by vaccination of naturally infected animals during the 
incubation period. The influence of vaccination with VVTGgRAB, both on the onset of the disease, 
and on the delay before death in foxes previously infected with wild rabies virus, has been 
investigated (Brochier et al., 1989a). The results show that 'early' and 'late' deaths occur as a 
consequence of interaction between oral vaccination with VVTGgRAB and rabies infection, but 
preclude the risk of the emergence of asymptomatic carriers of wild rabies virus after vaccination. 
It is also preferable that a vaccine virus used for oral vaccination of wildlife should not be 
horizontally transmitted to unvaccinated animals. No transmission of immunizing amounts of 
VVTGgRAB was found to occur in adult and young foxes. Changes in tissue tropism were not 
observed (Thomas et al., 1990). In areas of Europe earmarked for vaccine distribution several non 
target wild species were chosen for safety testing both because of their opportunistic feeding 
behaviour, and because of their presence (Brochier et al., 1989b); similar experiments were 
carried out on wild species from North America. In every case, the recombinant virus was 
perfectly safe. More recent experiments have also shown that the recombinant virus, 
administered either by scarification or by the oral route, is also safe for squirrel monkeys (Saimiri 
sciureus) and for chimpanzees (Pan troglodytes) (Rupprecht et al., 1992). 
Additional experiments were performed on several domestic and laboratory species in contact 
with control animals to test for horizontal transmission of VVTGgRAB. Without exception, the 
results showed that no horizontal transmission took place (Pastoret et al., 1992). 
The only remaining perceived risk to be investigated was the eventual recombination of the 
recombinant virus with a wild orthopox virus. For such an event to occur, both parental viruses 
must multiply during the same period of time in the same cells of the same animal. As no 
serological evidence for orthopoxvirus infection in the fox population has been found, the risk 
may be discarded in the main target species. Moreover, experimental inoculation of cowpox virus 
into foxes via the oral route results in viral multiplication only at a low level and for a short 
duration in the mouth cavity (Boulanger et al., 1994). 
Development of a vaccine bait system 
The development of an efficient baiting system is important since an attractive bait permits the 
self-vaccination of the target species. 
The VVTGgRAB vaccine suspension consists of the supematent fluid from a BHK cell culture 
infected with VVTGgRAB. The viral suspension medium is a saline solution with gentamycin added 
(125 µg/dose). 
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The baiting system is formed from an appetent mixture of fish meal (50%) and fish oil (11%) 
aggregated using a hydrophobic synthetic polymer (11%). A sealed polyethylene sachet 
containing 2.5 ml liquid vaccine (titrating 108 to 109 CCID50) is fixed into the bait with a binding 
agent (11%). 
Tetracycline hydrochloride, introduced into the appetent mixture bait (150 mg/ bait) serves as a 
biomarker of uptake of bait. 
This machine-made vaccine bait system (RABORAL®) forms a rigid 5 X 3 X 2 cm parallelipiped (a 
solid body of which each face is a parallelogram) weighing from 34 to 40g. 
The RABORAL® vaccine bait can be stored without freezing (at 4°C) and because of its mechanical 
resistance can be dropped by air. The efficacy and especially the attractive power of this baiting 
system to the red fox was established in an experimental station (Brochier et al., 1990a) and in the 
field (Brochier et al., 1990b). 
Deliberate release of the vaccinia-rabies recombinant 
virus 
PRELIMINARY LIMITED FIELD TRIAL 
Taking into account all the available experimental data concerning the safety of the VVTGgRAB for 
target and non-target species and its efficacy in foxes, an initial limited field trial of fox 
vaccination was authorized by the Belgian Public Health Authority. The site chosen was a military 
field, isolated from public and domestic animals (Marche-en-Famenne). In this trial, each capsule 
containing a suspension of 108 TCID50 of VVTGgRAB was introduced into a chicken head. On 17 and 
18 October 1987, 250 vaccine-baits were manually delivered over a 6 km2 area situated in the 
centre of the military field and surrounded by a non-vaccinated buffer zone. By day 15, the bait 
uptake was 64%. Of 145 rodents trapped in the baited area, only four had eaten baits and none 
showed any lesion that could be related to poxvirus infection (Pastoret et al., 1988). 
ENLARGED SCALE FIELD TRIAL 
The VVTGgRAB safety having been confirmed, the Belgium Ministry of Public Health on 21 
September 1988 gave authorization for an enlarged open field trial. This latter was conducted in a 
435 km2 area covering four administrative districts in the Province of Luxembourg (South 
Belgium) (Brochier et al., 1990b). This vaccination zone was chosen because it has the lowest 
human population density in the country (42 inhabitants/km2) combined with a high incidence of 
rabies. Furthermore, the region is characterized by various habitats including most of animal 
species which could consume baits. 
The vaccine used was a suspension of 108 TCID50 of VVTGgRAB contained in a plastic sachet. After 
the distribution of baits, field and laboratory controls confirmed the efficiency and stability of the 
vaccine bait association. Despite important variations of environmental temperatures 
(occurrence of natural freezing-thawing cycles), the VVTGgRAB bait system remained stable and 
attractive after one month in the field. 
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As far as the safety of this vaccination campaign is concerned, no abnormal morbidity or 
mortality was observed in wildlife or in domestic animals. Moreover, 12 months' monitoring failed 
to detect any ecological hazard or problem of public heath. 
 
Figure 1. Geographical distribution of 841 animal rabies cases in Belgium in 1989. Black dots: 520 wild animals; 
white dots: 321 domestic animals. Infected area: 10,000 km 2• F: France; G: Germany; L: Grand Duchy of Luxemburg; N: 
the Netherlands. 
 
Table 1. Protocol of fox vaccination campaigns in belgium 
 
aAttenuated strain of rabies virus - bVaccinia-rabies glycoprotein recombinant virus - cNot yet performed. 
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Figure 2. Geographical distribution of animal rabies cases: a. in 1992, b. in 1993. c. in 1994 (data until 15 
August). Black dots: wild animals; white dots: domestic animals. 
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EXPERIMENTAL LARGE-SCALE CAMPAIGNS OF FOX VACCINATION 
For evaluating the efficacy of the method, three fox vaccination campaigns using the 
VVTGgRAB were carried out in Belgium in November 1989, April 1990 and October 1990 (Brochier 
et al., 1991a, b). 
Twenty-five thousand machine made baits each containing 108 TCID50 of VVTGgRAB were each 
time dropped by helicopters in a 2200 km2 area in south Belgium (province of Luxembourg). 
Baits were dispersed in the field at a mean density of 15 baits/km2 • After bait dispersal, 81% of 
foxes inspected were positive for the tetracycline biomarker and only one rabid fox was 
detected close to the periphery of the treated area. No case of rabies, either in foxes or in 
domestic livestock, has been reported in the area. 
 
National programme of fox rabies elimination 
As shown in Fig. 1, Belgium was heavily infected before the campaigns of fox vaccination. The 
rabies infected area covered 10 000 km2 in the southern part of the country. Rabies has been 
endemic since 1981 and its incidence remained high, especially during 1989 when 841 animal 
rabies cases were recorded. Five campaigns of fox vaccination, covering the whole infected area, 
were carried out from autumn 1989 until 1991 (Table 1) (Brochier et al., 1991b; Coppens et al., 
1992). The two first campaigns (Autumn 1989, Spring 1990) were carried out using both 
attenuated rabies virus strain (SAD B 19) and recombinant vaccinia-rabies virus as vaccines. 
Since autumn 1990, the VVTGgRAB was used exclusively. Each time, 150 000 vaccine baits were 
dispersed by air (helicopter or plane) according to a grid resulting in a mean density of 15 
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baits/km2 ; urban areas and stretches of water were not seeded. 
After each vaccination campaign, foxes found dead or shot by hunters were collected for bone 
tetracycline analysis (bait uptake control) and rabies diagnosis. Tetracycline was detected in 
animal bones (left jaw) by ultraviolet fluorescence microscopy of a 400 µm transverse section 
(diamond saw, Isomet-Buchler). The presence of brain rabies virus was determined by 
immunoftuorescence and inoculation of murine neuroblastoma cells as recommended by the 
World Health Organization (1992). 
These 5 "full" campaigns induced a drastic decrease in the incidence of rabies and the 
elimination of the disease from 80% of the initial infected area (Fig. 2 and Fig. 3a). Regarding the 
geographical evolution of rabies in Belgium and in adjacent regions in neighbouring countries, 
new spatial strategies for bait dispersal were planned for 1992, 1993 and 1994 : successive 
restricted campaigns were carried out along political borders only (Table l) (Brochier et al., 1993, 
1994). These campaigns combined with vaccination operations in neighbouring countries 
induced a new decrease of incidence (Fig. 3a) ; no rabid foxes could be detected in 1993 in spite 
of an improved epidemiological surveillance (488 collected foxes were shown to be rabies 
negative). Nevertheless, rabies was observed in a badger and a domestic cat found close to 
international borders (Fig. 2b). Both of these rabies cases confirmed in the laboratory and 
nucleotide sequencing of these isolates demonstrated that they originated from the enzootic fox 
virus, demonstrating the persistence of undetected rabies foci of fox origin in Belgium (Bourhy, 
personal communication). 
In 1994 (data until 15 August), rabies was confirmed again in 13 foxes collected in a region 
situated close to the border with France (Fig. 2c). These cases demonstrate the persistence of a 
border rabies focus and justify further restricted campaigns of vaccination in both countries. 
Positive ethical and economical consequences of fox rabies control were obtained in the fields 
of public health, domestic animal health and environmental monitoring. Because notification of 
cases of rabies in cattle is mandatory in Belgium the incidence of rabies in domestic livestock 
provides a reliable indicator of the prevalence of rabies in the wild. Fig. 3b plots the number of 
notified cases of rabies in cattle over a 12 year period before and during the vaccination 
campaigns. No case of cattle rabies has been recorded in Belgium since December 1992. 
Similarly, as a second consequence of fox rabies control, only one rabies case was reported in 
domestic carnivores for two years (Fig. 3b). This could have a beneficial effect on the free 
movement of pets within the European Union by abolishing quarantine containment in some 
disease-free countries. 
The number of people who received medical treatment (curative vaccination schedule) after 
coming in contact with a suspected animal has also decreased markedly (Fig. 3c). 71 people 
were treated in 1993, only 6 of whom were confirmed to have been exposed to an infected 
animal during that year. 
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Figure 3. a. Animal rabies incidence in Belgium; data until 15 August 1994, b. Rabies in cattle (full columns) and 
domestic carnivores (hatched columns); data until 15 August 1994. c. Evolution of human vaccinations 
(postexposure schedule); data until 31 December 1993. Black arrows: "full" campaigns of fox vaccination 
(10,000 km2) white arrows: "restricted" campaigns (8500 km2 --> 2500 km 2). 
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Because of its efficacy, innocuity and heat-stability, the VVTGgRAB seems to offer an excellent 
alternative to the attenuated strains of rabies virus currently used in the field. Furthermore, the 
bait used is attractive, efficient and stable. In addition to the efficiency of a vaccine bait system, 
the strategy of bait delivery is of major importance for achieving the immunization of the required 
fraction of the fox population and, subsequently, the disruption of the viral infection cycle. Both 
spatial and temporal patterns of the bait distribution must be planned according to several 
natural factors. In this sense, the heat-stability of the VVTGgRAB bait system provides flexibility in 
planning a campaign. 
Sylvatic rabies has been eliminated from the majority of the initial infected area of Belgium after 
five fox vaccination campaigns. Nevertheless, the creation of immune belts along borders was 
required to prevent spread of rabies from infected regions in neighbouring countries. A 
surveillance area, including Belgium and adjacent regions in neighbouring countries 50 km 
around Belgium, has been defined. Further spatial strategies or potential cessation of fox 
vaccination will depend on the rabies evolution in this surveillance area. A complete cessation 
will be justifiable when this zone will have been rabies-free for one year. 
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